Topical imiquimod for the treatment of cutaneous leishmaniasis in an infant
Topical imiquimod for the treatment of cutaneous leishmaniasis in an infant
About this course
- Released:
- Expires: April 8, 2036
Target Audience
This activity is intended for practicing dermatologists and other physicians involved in the treatment and management of diseases of the skin.
Learning Objective
To understand the immunological mechanism of action of topical imiquimod and its potential role as a treatment option for
cutaneous leishmaniasis (CL) in infants as well, as to recognize the clinical presentation and therapeutic challenges of cutaneous
leishmaniasis in infants, and to evaluate topical imiquimod as an alternative to systemic treatment in this population.
Accreditation and Designation Statement
Once the test is passed, a certificate of completion will be generated. The learning activity can be added to the Royal College of Physicians' CPD diary as a self-certified entry.
Activity Disclosures
No commercial support has been accepted related to the development or publication of this activity.